Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 ...

Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of ...

A 2023 graduate of Signal Mountain Middle/High School is a member of the Georgia Tech team that won a BIG international ...

Recent developments in health include EU's advice on cereulide toxin in infant formula leading to recalls, FDA's rejection of ...

Whether it’s at first pitch, opening tip or kickoff, you’ll find pharma brands all across the wide world of sports. In recent years, pharma brands have embraced sponsorship opportunities with various ...

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from ...

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

Sanofi’s venglustat showed a meaningful change in patients with Gaucher disease but not in patients with Fabry disease.

Sanofi halts plan mRNA seasonal flu vaccine, stopping phase 1 trial but continues work on mRNA pandemic flu vaccine with promising data.

Influenza A rates have remained stable, but influenza B is starting to spread. This comes as the CDC reports evidence of a covid upsurge in 11 states and respiratory syncytial virus in 21 states. Plus ...

Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and ...

Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.